This bill amends section 461.007 of the Florida Statutes to require that only certain podiatric physicians, specifically those registered with the United States Drug Enforcement Administration and authorized to prescribe controlled substances, complete specified continuing education for license renewal. Additionally, the bill creates a new section, 461.011, which establishes guidelines for podiatric physicians performing stem cell therapy that is not approved by the FDA. It emphasizes the ethical sourcing of stem cells, requiring that they be obtained from facilities adhering to current good manufacturing practices and that physicians provide clear notices in advertisements regarding the unapproved status of such therapies.

The new section outlines the definitions and conditions under which podiatric physicians may perform stem cell therapy, including the necessity of obtaining informed consent from patients and the inclusion of specific information in advertisements. It also establishes penalties for violations, including disciplinary actions and criminal penalties for serious infractions, such as using stem cells derived from aborted fetuses. The bill aims to promote medical innovation while ensuring ethical standards and patient safety in the practice of podiatric medicine. The act is set to take effect on July 1, 2026.

Statutes affected:
S 1092 Filed: 461.007